{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-077792","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.409091+00:00","generated_at":"2026-06-26T21:57:22.503994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022","bullets":["FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.","Cash and equivalents $149M as of Dec 31, 2021, expected to fund operations into 2024.","Q4 2021 net loss $16M vs net income $7.8M in Q4 2020; full year net loss $110.7M.","Phase 2 PRECISION 1 trial (TSC1/TSC2 alterations) open; initial data expected H1 2023.","Operating expenses Q4 $16.9M, up from $5.7M; G&A increased due to commercial buildout."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-077792","json":"https://secwatch.observer/filing/0001193125-22-077792.json","markdown":"https://secwatch.observer/filing/0001193125-22-077792.md","text":"https://secwatch.observer/filing/0001193125-22-077792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/0001193125-22-077792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522077792/d326646d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:57:22.503994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}